Skip to main content

CPRX

Stock
Health Care
Biotechnology

Performance overview

CPRX Price
Price Chart

Forward-looking statistics

Beta
Risk

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

Company info

SectorHealth Care
IndustryBiotechnology
Employees119
Market cap$1.8B

Fundamentals

Enterprise value$2.1B
Revenue$534.6M
Revenue per employee
Profit margin36.91%
Debt to equity0.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$1.57
Dividend per share
Revenue per share$4.47
Avg trading volume (30 day)$28M
Avg trading volume (10 day)$30M
Put-call ratio

Macro factor sensitivity

Growth+0.9
Credit+4.4
Liquidity+1.6
Inflation-4.1
Commodities-1.5
Interest Rates-3.1

Valuation

Dividend yield0.00%
PEG Ratio14.21
Price to sales4.90
P/E Ratio14.21
Enterprise Value to Revenue3.87
Price to book3.29

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research (July 21, 2025)
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats

Innovation is at its peak in the Zacks Medical-Drugs industry. CPRX, ZVRA, TBPH, ALDX and LRMR may prove to be good additions to one's portfolio.

Zacks Investment Research (July 16, 2025)
CPRX or STVN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Drugs stocks are likely familiar with Catalyst Pharmaceutical (CPRX) and Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research (July 9, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free